Cyteir was a clinical-stage oncology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir had CYT-0851 in development in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 128 Spring St, Building A
- Phone
- 312-953-3651
- in****@****ier.com
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- cyteir.com
- Keywords
- Lexington.
- HQ
- Lexington, MA
Cyteir Therapeutics Questions
Cyteir Therapeutics's helpline number is 312-953-3651
Cyteir Therapeutics's website is cyteir.com
Cyteir Therapeutics's LinkedIn profile is https://www.linkedin.com/company/cyteir-therapeutics
Cyteir Therapeutics has
2 employees.
View email and phone details for 2
employees at Cyteir Therapeutics.
Cyteir Therapeutics's industry is
Research Services
Cyteir Therapeutics's top competitors are
Cabaletta Bio,
Alkeus Pharmaceuticals, Inc.,
Scorpion Therapeutics,
Lifemine Therapeutics,
Kelonia Therapeutics,
C4 Therapeutics, Inc.,
Monomoy Advisors,
Crossbow Therapeutics, Inc,
Kymera Therapeutics,
Editas Medicine.
Cyteir Therapeutics's support email address is info@cytier.com
Cyteir Therapeutics's categories are Research Services
Cyteir Therapeutics's founding year is 2012
